Custom service
Metabolite Identification Platform
Identify and characterize peptide metabolites from in-vitro systems
Metabolite Identification Platform supports programmes that identify and characterize peptide metabolites from in-vitro systems. In a typical engagement we plan the protease and plasma incubation panels route first, confirm compatibility with LC-MS/MS metabolite mapping, and release metabolite ID report with cleavage map on a 3–6 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep protease and plasma incubation panels as the primary option and hold LC-MS/MS metabolite mapping in reserve, so that scale-up never depends on an unproven step.
Predicting in-vivo degradation pathways
Designing metabolically stable analogs
In-vivo ADME studies
Targets with no assayable readout and no purified protein available
Screening programmes close with a data package: primary screen statistics, confirmation data for each hit, counterscreen results and resynthesized material. Library lots ship with composition QC — representation and identity checks by LC-MS or NGS as the format requires.
Service Highlights
- Protease and plasma incubation panels as the default route, with LC-MS/MS metabolite mapping held as a proven fallback
- Cleavage-site assignment worked into the design where the application requires it
- Every reported hit is confirmed by independent resynthesis and re-testing before it reaches you
- Analytical confirmation of every intermediate before the final release
- Library integrity (composition, representation) is measured, not assumed, before screening begins
- Metabolite ID report with cleavage map delivered with a complete conjugation or synthesis certificate
How the work runs
Library design
Diversity, degeneracy and deconvolution strategy for Metabolite Identification Platform are fixed in a design document.
Library synthesis or construction
The library is built with protease and plasma incubation panels and its composition is QC'd before screening.
Primary screening
Screening runs with LC-MS/MS metabolite mapping, with controls and statistics defined in advance.
Hit deconvolution
Hits are identified and ranked; counterscreens remove non-specific and promiscuous binders.
Hit confirmation
Every hit is resynthesized and re-tested; only reproducible hits advance.
Hit delivery
Confirmed hits and Metabolite ID report with cleavage map are delivered with the full screening data package.
Specifications & timeline
- Turnaround
- 3–6 weeks
- Typical scale
- 10^2 – 10^9 members by format
- Chemistry options
- protease and plasma incubation panels; LC-MS/MS metabolite mapping; cleavage-site assignment
- Deliverable
- Metabolite ID report with cleavage map
- QC package
- Library composition QC, screening raw data, hit confirmation package
- Shipping
- Ambient (plates, beads) or dry ice (display libraries)
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.